Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech growth

Evotec SE, a German drug discovery powerhouse, continues to advance partnerships with major US pharma firms, positioning it as a key player for American investors tracking biotech innovation and outsourcing trends.

Evotec SE maintains its role as a leading contract research organization in drug discovery, recently highlighted for ongoing collaborations that underscore its relevance in the global biotech sector. The company reported steady progress in its pipeline partnerships during its last quarterly update published on May 10, 2025, according to Evotec IR as of 05/10/2025.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Evotec SE
• Sector/industry: Biotechnology / Drug Discovery
• Headquarters/country: Germany
• Core markets: US, Europe
• Key revenue drivers: Partnerships, milestones, royalties
• Home exchange/listing venue: Nasdaq Frankfurt (EVT)
• Trading currency: EUR

Evotec SE: core business model

Evotec SE operates an industrialised drug discovery and development platform, focusing on partnering with pharmaceutical and biotech companies to advance novel therapies. The company integrates AI-driven technologies with wet-lab capabilities across multiple therapeutic areas including oncology, neurology, and infectious diseases. Headquartered in Hamburg, Germany, Evotec employs over 4,000 scientists globally, with significant operations in the US through its Princeton, New Jersey site.

This asset-agnostic model allows Evotec to de-risk R&D for partners by sharing costs and risks, earning upfront payments, milestones, and royalties upon success. For US investors, Evotec's exposure to the world's largest pharma market is notable, as roughly 50% of its revenue stems from North American collaborations as per the 2024 annual report published March 28, 2025, according to Evotec annual report as of 03/28/2025.

Main revenue and product drivers for Evotec SE

Evotec's revenue is primarily driven by integrated drug discovery services and co-development deals. Key partnerships include multi-year agreements with US giants like Bristol Myers Squibb and Janssen, contributing recurring income through research fees and success-based payments. In Q1 2025, group revenues reached €248 million, up 4% year-over-year, driven by milestones in neurology programs, as detailed in the quarterly statement released May 10, 2025, via Evotec IR as of 05/10/2025.

Royalties from approved drugs like those from past collaborations represent a smaller but growing portion, with potential upside from over 20 clinical-stage assets partnered externally. The company's Just Evotec Biologics division adds manufacturing capabilities, serving US clients in antibody development.

Industry trends and competitive position

The biotech sector faces pressure to cut R&D costs amid patent cliffs, boosting demand for outsourced discovery platforms like Evotec's. Competitors such as Charles River Laboratories and WuXi AppTec vie for similar mandates, but Evotec differentiates through its end-to-end platform and AI integration. A 2025 IQVIA report notes CRO market growth at 8% CAGR through 2030, with Europe-US hubs like Evotec capturing share, according to IQVIA as of 02/15/2025.

Why Evotec SE matters for US investors

Listed on Nasdaq Frankfurt, Evotec offers US investors access to European biotech efficiency with heavy US revenue reliance. Its partnerships with American Big Pharma provide indirect exposure to blockbuster pipelines without single-asset risk. Trading at levels reflecting steady execution, the stock aligns with themes of R&D outsourcing pivotal to US healthcare innovation.

Conclusion

Evotec SE stands as a resilient player in drug discovery outsourcing, with a robust partnership model fueling growth amid industry shifts. Recent quarterly figures affirm operational stability, while US-centric deals enhance its appeal. Investors monitoring biotech services will note its strategic positioning, though execution on milestones remains key.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.